A method of proteolyzing a protein, including immobilizing a protein in at least one pore of a porous body, and contacting the protein immobilized in the pore and a protease immobilized on a solid surface such that the protease selectively accesses a site of the protein and proteolyzes the protein at the site.

The present disclosure relates to systems and methods of using machine learning analysis to stratify the risk of spontaneous preterm birth (SPTB). In some variations, to select informative markers that differentiate SPTB from term deliveries, a processed quantification data of the markers can be subjected to univariate receiver operating characteristic (ROC) curve analysis. A Differential Dependency Network (DDN) can then applied in order to extract co-expression patterns among the markers. In order to assess the complementary values among selected markers and the range of their relevant performance, multivariate linear models can be derived and evaluated using bootstrap resampling.

The present invention provides a detection method for a monoclonal antibody in a sample, comprising: (a) a step of capturing the monoclonal antibody in the sample and immobilizing the monoclonal antibody in pores of a porous body; (b) a step of bringing the porous body in which the monoclonal antibody is immobilized with nanoparticles on which protease is immobilized to conduct selective protease digestion of the monoclonal antibody; (c) a step of detecting, by a liquid chromatography mass spectrometry (LC-MS), peptide fragments obtained by the selective protease digestion; and (a) a step of conducting a reduction reaction under an acidic condition after the step (a). By the present invention, further applicability of the detection method for the monoclonal antibodies using mass spectrometry is expected.

Methods and kits for detecting and/or quantitating target proteins in biological samples. In particular, the method comprises capture and immobilization of the target protein, protein denaturation, proteolytic digestion, and analysis using a mass spectrometry-based technique.

An assay device including a loading zone for a sample that may contain an analyte, an activator in communication with the loading zone from which at least one activator is displaced by presence of the analyte, an amplifier in an inactive state in communication with the activator that becomes activated in the presence of the activator, a biomatrix barrier in communication with the activated amplifier that is degraded or modified by the activated amplifier, and an indicator responsive to the degradation or modification of the biomatrix barrier, which in turn reflects a concentration of the analyte in the sample loaded on the device. The selection of analyte or displacement of the activator by presence of the analyte may occur off-platform and/or may rely on use of non-covalent interactions. The activator may include an enzyme or other reagent that activates the amplifier. Also, associated methods.

An enzyme-responsive peptide and a method off using such enzyme-responsive peptide are disclosed. An enzyme-responsive peptide, the peptide comprising an amino acid having an -amino group, an -carboxylic acid group and a -amine group, wherein the -amine group is covalently bonded with a first group and the -carboxylic acid is covalently bonded with a second group.

The present invention provides a method in which a porous body having a monoclonal antibody to be measured immobilized in pores thereof is brought into contact with nanoparticles having a protease immobilized thereonto in a liquid to perform selective protease digestion of the monoclonal antibody and a peptide fragment obtained by the digestion is detected by liquid chromatography mass spectrometry (LC-MS), wherein the monoclonal antibody is digested with the protease in the presence of an antibody specifically binding to the monoclonal antibody or a target molecule of the monoclonal antibody.

A therapeutic composition for the treatment of the symptoms of Williams Syndrome and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of Williams Syndrome, or the likelihood of an individual to develop Williams Syndrome is disclosed.

A method of proteolyzing a protein, including immobilizing a protein in at least one pore of a porous body, and contacting the protein immobilized in the pore and a protease immobilized on a solid surface such that the protease selectively accesses a site of the protein and proteolyzes the protein at the site.

The subject of the invention is a new compound of the following chemical formula:
ABZ.sup.1-Dap(O2(Cbz)).sup.2-Dap(O1).sup.3-Dap(O2).sup.4-Arg.sup.5-ANB.sup.6-NH.sub.2 where: ABZ stands for 2-aminobenzoic acid; DAP stands for diaminopropanoic acid (Dap) derivatives, modified by the functionalised residues of mono-ethylene or diethylene glycol (PEG); ANB stands for 5-amino-2-nitrobenzoic acid The subject of the invention is a method for producing the new compound and a pharmaceutical solution for cancer detection, which contains the above-mentioned compound. The subject of the invention is a method for cancer detection through the in vitro analysis of a human urine sample to which a new compound is added and blended with a buffer of pH 7-9. The subject of the invention is also a kit for detecting cancer, in particular bladder cancer, and the use of hydrolysis of the new compound in the position no. 5 by proteasome 20s for cancer detection, in particular bladder cancer.